# Devdatt Kurdikar

> Devdatt (Dev) Kurdikar is chairman, president and CEO of embecta. A chemical engineer with an MBA, he previously led Cardiac Science, held management roles at American Medical Systems and Boston Scientific, and spent eleven years at Baxter. His career includes business turnarounds, a carve-out, integration work and embecta’s 2022 separation from BD.

- **Role:** Chairman, President and Chief Executive Officer at embecta
- **Organizations:** embecta, Zimmer Biomet, AdvaMed, LMG Holdings, BD, Cardiac Science Corporation, Boston Scientific, American Medical Systems, Baxter International, Monsanto
- **Education:** Bachelor’s degree in Chemical Engineering, University of Bombay, Master of Science in Chemical Engineering, Washington State University, Ph.D. in Chemical Engineering, Purdue University, Master of Business Administration, Washington University in St. Louis
- **Known for:** Led Cardiac Science through a return to profitable growth and its sale to ZOLL., Led a business carve-out, sale and subsequent integration from American Medical Systems into Boston Scientific., Led embecta as it became an independent public company in April 2022.

## Career timeline

- **Early career** — Began as a senior research engineer at Monsanto.
- **Before 2013** — Spent eleven years at Baxter in finance, strategy, integration, R&D planning, operations and marketing.
- **2011-2013** — Vice President, Marketing at Baxter.
- **2013** — Joined American Medical Systems as vice president and general manager; subsequently led the business through a carve-out and sale to Boston Scientific.
- **2015-2016** — Vice president and general manager at Boston Scientific; led integration of the acquired business.
- **2016-2019** — President and CEO of Cardiac Science Corporation.
- **2021** — Joined BD as worldwide president of its business that later became embecta, effective February 10.
- **2022** — Became president, CEO and a director of embecta at its April 1 spinoff from BD.
- **2024** — Appointed to Zimmer Biomet’s board on June 20.
- **2026** — Elected chairman of embecta on February 11, retaining president and CEO roles.

## Achievements

- Led Cardiac Science through a return to profitable growth and its sale to ZOLL.
- Led a business carve-out, sale and subsequent integration from American Medical Systems into Boston Scientific.
- Led embecta as it became an independent public company in April 2022.
- Became an independent director of Zimmer Biomet in June 2024.
- Elected embecta chairman in February 2026.

## Latest updates

- **2026-08** — embecta reported third-quarter fiscal 2026 results on August 7.
- **2026-05** — embecta completed its acquisition of Owen Mumford on May 15, following an agreement for £100 million upfront and up to £50 million in performance-based payments.
- **2026-02** — Elected chairman of embecta effective February 11; Claire Pomeroy became lead independent director.

## Links

- Website: https://www.embecta.com/
- LinkedIn: https://www.linkedin.com/in/dev-kurdikar

---

Profile page: https://yespress.io/devdatt-kurdikar
Published by YesPress — https://yespress.io
Last updated: 2026-10-22